Evgen Pharma PLC Option over new sulforaphane analogues (7343Y)
18 Enero 2022 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 7343Y
Evgen Pharma PLC
18 January 2022
Evgen Pharma plc
("Evgen" or "the Company")
Option over new sulforaphane analogues
Evgen Pharma plc (AIM: EVG), the clinical stage drug development
company developing sulforaphane-based medicines for the treatment
of multiple diseases, announces a Memorandum of Understanding with
the University of Seville ('US'), Consejo Superior de
Investigaciones Científicas ('CSIC') and Fundación Pública Andaluza
Progreso y Salud on behalf of the Institute of Biomedicine of
Seville, for second generation sulforaphane analogues.
Under the agreement Evgen has signed an exclusive option to
license new, novel sulforaphane analogues synthesised by these
Spanish institutions, subject to a fixed evaluation period. These
analogues have the potential for differentiation from SFX-01 in
terms of product formulation. They may also have the potential for
differential activity against targets that Evgen is pursuing such
as STAT3, SHP2 and Nrf2. As such, they could constitute follow-on
and/or alternative products which would expand Evgen's development
and partnering opportunities.
If the option is exercised it would expand substantially Evgen's
preclinical pipeline of sulforaphane analogues. Analogues from an
existing license from US and CSIC are currently undergoing further
screening against relevant targets. The current option will be
exercised should the Company's technical evaluation be
positive.
Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I
am delighted that we are extending our collaboration with the CSIC
and University of Seville, and the opportunity this gives us to
broaden our sulforaphane-based drug pipeline. If differentiation is
demonstrated in the laboratory, we then have considerable potential
to target diseases where one of the key molecular targets for
sulforaphane is more relevant than others, enhancing our pipeline
substantially."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7876 741 001 / + 44 (0)7867
Anna Dunphy / Phillip Marriage 984 082
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects. SFX-01 has demonstrated efficacy in a Phase
II trial for advanced metastatic breast cancer. It has been used to
treat over 200 patients in clinical trials and is well-tolerated
with predominately mild side-effects.
The Company has its headquarters at Alderley Park, Cheshire, and
its registered office is at the Liverpool Science Park, Liverpool.
It is listed on the AIM market of the London Stock Exchange and
trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLTLAIDLIF
(END) Dow Jones Newswires
January 18, 2022 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024